RINVOQ EXTENDED-RELEASE TABLET 15MG

Product Information

Registration Status: Active

RINVOQ EXTENDED-RELEASE TABLET 15MG is approved to be sold in Singapore with effective from 2020-06-16. It is marketed by ABBVIE PTE LTD, with the registration number of SIN15959P.

This product contains Upadacitinib 15mg in the form of TABLET, FILM COATED, EXTENDED RELEASE. It is approved for ORAL use.

This product is manufactured by AbbVie Ireland NL B.V. in IRELAND, andAbbVie S.r.l. (Primary and Secondary Packager) in ITALY.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Upadacitinib


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank